36671394|t|Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.
36671394|a|Parkinson's disease is the second most common neurodegenerative pathology. Due to the limitations of existing therapeutic approaches, novel anti-parkinsonian medicines with non-dopamine mechanisms of action are clearly needed. One of the promising pharmacological targets for anti-Parkinson drug development is phosphodiesterase (PDE) 10A. The stimulating motor effects of PDE10A inhibition were detected only under the conditions of partial dopamine depletion. The results raise the question of whether PDE10A inhibitors are able to restore locomotor activity when dopamine levels are very low. To address this issue, we (1) developed and validated the rat model of acute severe dopamine deficiency and (2) tested the action of PDE10A inhibitor MP-10 in this model. All experiments were performed in dopamine transporter knockout (DAT-KO) rats. A tyrosine hydroxylase inhibitor, alpha-Methyl-DL-tyrosine (alphaMPT), was used as an agent to cause extreme dopamine deficiency. In vivo tests included estimation of locomotor activity and catalepsy levels in the bar test. Additionally, we evaluated the tissue content of dopamine in brain samples by HPLC analysis. The acute administration of alphaMPT to DAT-KO rats caused severe depletion of dopamine, immobility, and catalepsy (Dopamine-Deficient DAT-KO (DDD) rats). As expected, treatment with the L-DOPA and carbidopa combination restored the motor functions of DDD rats. Strikingly, administration of MP-10 also fully reversed immobility and catalepsy in DDD rats. According to neurochemical studies, the action of MP-10, in contrast to L-DOPA + carbidopa, seems to be dopamine-independent. These observations indicate that targeting PDE10A may represent a new promising approach in the development of non-dopamine therapies for Parkinson's disease.
36671394	14	20	PDE10A	Gene	63885
36671394	30	33	Rat	Species	10116
36671394	50	58	Dopamine	Chemical	MESH:D004298
36671394	94	106	Non-Dopamine	Chemical	-
36671394	107	126	Parkinson's Disease	Disease	MESH:D010300
36671394	136	155	Parkinson's disease	Disease	MESH:D010300
36671394	182	209	neurodegenerative pathology	Disease	MESH:D019636
36671394	281	293	parkinsonian	Disease	MESH:D010300
36671394	309	321	non-dopamine	Chemical	-
36671394	417	426	Parkinson	Disease	MESH:D010302
36671394	447	475	phosphodiesterase (PDE) 10A.	Gene	63885
36671394	509	515	PDE10A	Gene	63885
36671394	578	586	dopamine	Chemical	MESH:D004298
36671394	702	710	dopamine	Chemical	MESH:D004298
36671394	790	793	rat	Species	10116
36671394	816	835	dopamine deficiency	Disease	MESH:C567730
36671394	865	871	PDE10A	Gene	63885
36671394	882	887	MP-10	Chemical	-
36671394	968	971	DAT	Gene	24898
36671394	976	980	rats	Species	10116
36671394	984	1004	tyrosine hydroxylase	Gene	25085
36671394	1016	1040	alpha-Methyl-DL-tyrosine	Chemical	MESH:D019805
36671394	1042	1050	alphaMPT	Chemical	MESH:D019805
36671394	1091	1110	dopamine deficiency	Disease	MESH:C567730
36671394	1172	1181	catalepsy	Disease	MESH:D002375
36671394	1255	1263	dopamine	Chemical	MESH:D004298
36671394	1327	1335	alphaMPT	Chemical	MESH:D019805
36671394	1339	1342	DAT	Gene	24898
36671394	1346	1350	rats	Species	10116
36671394	1378	1386	dopamine	Chemical	MESH:D004298
36671394	1404	1413	catalepsy	Disease	MESH:D002375
36671394	1415	1423	Dopamine	Chemical	MESH:D004298
36671394	1434	1437	DAT	Gene	24898
36671394	1442	1445	DDD	Disease	MESH:C562924
36671394	1447	1451	rats	Species	10116
36671394	1486	1492	L-DOPA	Chemical	MESH:D007980
36671394	1497	1506	carbidopa	Chemical	MESH:D002230
36671394	1551	1554	DDD	Disease	MESH:C562924
36671394	1555	1559	rats	Species	10116
36671394	1591	1596	MP-10	Chemical	-
36671394	1632	1641	catalepsy	Disease	MESH:D002375
36671394	1645	1648	DDD	Disease	MESH:C562924
36671394	1649	1653	rats	Species	10116
36671394	1705	1710	MP-10	Chemical	-
36671394	1727	1745	L-DOPA + carbidopa	Chemical	-
36671394	1759	1767	dopamine	Chemical	MESH:D004298
36671394	1824	1830	PDE10A	Gene	63885
36671394	1892	1904	non-dopamine	Chemical	-
36671394	1919	1938	Parkinson's disease	Disease	MESH:D010300
36671394	Positive_Correlation	MESH:D019805	MESH:D002375
36671394	Association	MESH:D004298	63885
36671394	Association	MESH:D002230	MESH:C562924
36671394	Association	MESH:C562924	63885
36671394	Positive_Correlation	MESH:D019805	MESH:C567730
36671394	Association	MESH:D002375	63885
36671394	Negative_Correlation	MESH:D004298	MESH:D019805
36671394	Association	MESH:D010300	63885
36671394	Association	MESH:D010302	63885
36671394	Negative_Correlation	MESH:D019805	25085
36671394	Association	MESH:D007980	MESH:C562924
36671394	Association	MESH:D004298	24898

